Absolute and Functional Iron Deficiency Is a Common Finding in Patients With Heart Failure and After Heart Transplantation

Przybyłowski, Piotr; Wasilewski, Grzegorz; Gołąbek, Karolina; Bachórzewska−Gajewska, Hanna; Dobrzycki, Sławomir; Koc-Żórawska, Ewa; Małyszko, Jolanta

doi:10.1016/j.transproceed.2015.12.023

Cited by 26 publications

(25 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Likewise, CKD patients have high likelihoods of developing functional iron deficiency (FID) [278]. This complex disorder is characterized by TSAT levels that are less than 20%, due to bone marrow extracting iron from the circulation faster than the rate at which iron is released from stores, and in combination with serum ferritin levels that are normal or higher than 200 ng/mL, which depicts adequate or high iron stores [283,298]. The pathophysiology of FID is a consequence of systemic inflammation causing insufficient iron mobilization [273].…”

Section: Mechanisms Underlying Iron Dysregulation In Chronic Kidnementioning

confidence: 99%

The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia

Czaya

Faul

2019

IJMS

View full text Add to dashboard Cite

In patients with chronic kidney disease (CKD), adverse outcomes such as systemic inflammation and anemia are contributing pathologies which increase the risks for cardiovascular mortality. Amongst these complications, abnormalities in mineral metabolism and the metabolic milieu are associated with chronic inflammation and iron dysregulation, and fibroblast growth factor 23 (FGF23) is a risk factor in this context. FGF23 is a bone-derived hormone that is essential for regulating vitamin D and phosphate homeostasis. In the early stages of CKD, serum FGF23 levels rise 1000-fold above normal values in an attempt to maintain normal phosphate levels. Despite this compensatory action, clinical CKD studies have demonstrated powerful and dose-dependent associations between FGF23 levels and higher risks for mortality. A prospective pathomechanism coupling elevated serum FGF23 levels with CKD-associated anemia and cardiovascular injury is its strong association with chronic inflammation. In this review, we will examine the current experimental and clinical evidence regarding the role of FGF23 in renal physiology as well as in the pathophysiology of CKD with an emphasis on chronic inflammation and anemia.

show abstract

Section: Mechanisms Underlying Iron Dysregulation In Chronic Kidnementioning

confidence: 99%

The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia

Czaya

Faul

2019

IJMS

View full text Add to dashboard Cite

show abstract

“…ID constitutes a frequent co-morbidity in patients with HF, and its prevalence varies according to the clinical characteristics of the studied cohort and the applied definition of ID. Based on laboratory tests (the only study investigating ID in HF based on bone marrow aspirates is presented in Table 1 ), the prevalence of ID in HF ranges from 33 to 74% [ 14 , 23 , 24 , 26 , 45 – 53 ], with higher rates in anaemics versus non-anaemics [ 14 , 23 , 24 , 26 , 45 , 48 , 49 ] and decompensated [ 26 , 52 , 54 , 55 ] versus stable HF [ 14 , 23 , 24 , 45 – 51 , 53 , 56 – 58 ] (Table 1 ).…”

Section: Prevalence Of Id In Hfmentioning

confidence: 99%

Iron Therapy in Patients with Heart Failure and Iron Deficiency: Review of Iron Preparations for Practitioners

Drozd

Jankowska

Banasiak³

et al. 2016

Am J Cardiovasc Drugs

View full text Add to dashboard Cite

In patients with heart failure (HF), iron deficiency (ID) correlates with decreased exercise capacity and poor health-related quality of life, and predicts worse outcomes. Both absolute (depleted iron stores) and functional (where iron is unavailable for dedicated tissues) ID can be easily evaluated in patients with HF using standard laboratory tests (assessment of serum ferritin and transferrin saturation). Intravenous iron therapy in iron-deficient patients with HF and reduced ejection fraction has been shown to alleviate HF symptoms and improve exercise capacity and quality of life. In this paper, we provide information on how to diagnose ID in HF. Further we discuss pros and cons of different iron preparations and discuss the results of major trials implementing iron supplementation in HF patients, in order to provide practical guidance for clinicians on how to manage ID in patients with HF.

show abstract

“…Stephan von Haehling kamen bei 9,8 % der Studienteilnehmer vor. Diese Daten unterstreichen die Häufigkeit des Eisenmangels im klinischen Alltag und stimmen mit früher veröffentlichten Studiendaten überein, die eine Prävalenz von etwa 35-50 % annahmen [4].…”

Section: Eisenmangel Bei Herzinsuffizienz: Ein Kurzer Leitfadenunclassified

Eisenmangel bei Herzinsuffizienz: ein kurzer Leitfaden

Haehling¹

2017

Kardio up

View full text Add to dashboard Cite

Absolute and Functional Iron Deficiency Is a Common Finding in Patients With Heart Failure and After Heart Transplantation

Cited by 26 publications

References 19 publications

The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia

The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia

Iron Therapy in Patients with Heart Failure and Iron Deficiency: Review of Iron Preparations for Practitioners

Eisenmangel bei Herzinsuffizienz: ein kurzer Leitfaden

Contact Info

Product

Resources

About